A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases

Zhizhen Li,Jianping Wu,Ji Zhou,Baoshi Yuan,Jiqiao Chen,Wanchen Wu,Lian Mo,Zhipeng Qu,Fei Zhou,Yingying Dong,Kai Huang,Zhiwei Liu,Tao Wang,Deebie Symmes,Jingliang Gu,Eiketsu Sho,Jingping Zhang,Ruihuan Chen,Ying Xu

DOI: https://doi.org/10.1128/mbio.02542-21

IF: 6.4

2021-10-13

mBio

Abstract:Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively profiled to identify potential anti-COVID-19 targets, new drugs with significant efficacy remain to be developed. Here, we report the potent preclinical efficacy of ALD-R491, a vimentin-targeting small molecule compound, in treating COVID-19 through its host-directed antiviral and anti-inflammatory actions. We found that by altering the physical properties of vimentin filaments, ALD-491 affected general cellular processes as well as specific cellular functions relevant to SARS-CoV-2 infection. Specifically, ALD-R491 reduced endocytosis, endosomal trafficking, and exosomal release, thus impeding the entry and egress of the virus; increased the microcidal capacity of macrophages, thus facilitating the pathogen clearance; and enhanced the activity of regulatory T cells, therefore suppressing the overactive immune responses. In cultured cells, ALD-R491 potently inhibited the SARS-CoV-2 spike protein and human ACE2-mediated pseudoviral infection. In aged mice with ongoing, productive SARS-CoV-2 infection, ALD-R491 reduced disease symptoms as well as lung damage. In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Our results indicate a unique mechanism and significant therapeutic potential for ALD-R491 against COVID-19. We anticipate that ALD-R491, an oral, fast-acting, and non-cytotoxic agent targeting the cellular protein with multipart actions, will be convenient, safe, and broadly effective, regardless of viral mutations, for patients with early- or late-stage disease, post-COVID-19 complications, and other related diseases. IMPORTANCE With the Delta variant currently fueling a resurgence of new infections in the fully vaccinated population, developing an effective therapeutic drug is especially critical and urgent in fighting COVID-19. In contrast to the many efforts to repurpose existing drugs or address only one aspect of COVID-19, we are developing a novel agent with first-in-class mechanisms of action that address both the viral infection and the overactive immune system in the pathogenesis of the disease. Unlike virus-directed therapeutics that may lose efficacy due to viral mutations, and immunosuppressants that require ideal timing to be effective, this agent, with its unique host-directed antiviral and anti-inflammatory actions, can work against all variants of the virus, be effective during all stages of the disease, and even resolve post-disease damage and complications. Further development of the compound will provide an important tool in the fight against COVID-19 and its complications, as well as future outbreaks of new viruses.

microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: to develop a new therapeutic drug that can both resist viruses and reduce inflammation for COVID - 19 and its related diseases. Specifically, the research aims to develop an oral small - molecule compound ALD - R491 by targeting the cytoskeletal protein vimentin to deal with SARS - CoV - 2 virus infection and the hyperactive host immune response triggered by it.

### Background of the paper and problem description

1. **Virus infection and immune response**
- The damage of COVID - 19 comes not only from the SARS - CoV - 2 virus itself but also from the hyperactive immune response of the host triggered by it.
- Treatment methods that simply reduce the viral load or suppress the excessive inflammatory response have failed to provide satisfactory efficacy in all cases.

2. **Limitations of existing treatment regimens**
- Most of the existing antiviral drugs and immunomodulators only target one aspect of the virus or the immune system, and may lose their effectiveness due to virus mutations.
- Immunosuppressants require precise timing of use, otherwise they may lead to disease deterioration.

3. **Innovative mechanism of targeting vimentin**
- Vimentin is an evolutionarily conserved intermediate filament protein and has multiple functions in healthy and diseased states.
- By changing the physical properties of vimentin, general cell processes and specific functions can be affected, thereby hindering virus entry, transport, and release, enhancing the bactericidal ability of macrophages, and activating regulatory T cells to suppress excessive immune responses.

### Mechanism of action of ALD - R491

- **Antiviral effect**
- ALD - R491 reduces endocytosis, endosomal transport, and exosome release by changing the dynamic properties of vimentin, thereby hindering virus entry and release.
- In vitro experiments, ALD - R491 significantly inhibited SARS - CoV - 2 spike protein - and ACE2 - mediated pseudovirus infections, with IC50 values of 13.5 nM, 34.7 nM, and 64.9 nM (MOI of 0.5, 5, and 50 respectively).

- **Anti - inflammatory effect**
- ALD - R491 enhances the bactericidal efficiency of macrophages, increases ROS production, and reduces the number of live Salmonella in macrophages.
- ALD - R491 directly activates regulatory T cells, enabling them to better control excessive immune responses, thereby reducing cytokine storms.

### Experimental results and clinical significance

- **In vivo experiments**
- In an aged mouse model, ALD - R491 showed significant therapeutic effects, reducing weight loss, lung congestion, and tissue damage, and decreasing the degree of diffuse alveolar damage.
- Different doses of ALD - R491 all showed good safety, with no obvious toxicity.

In conclusion, this research has developed a new oral small - molecule compound ALD - R491. By targeting vimentin, it can play antiviral and anti - inflammatory roles in multiple pathological processes, providing new ideas and tools for the treatment of COVID - 19 and its related diseases.